AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 135 filers reported holding AMYLYX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,518,046 | -44.5% | 137,523 | -34.6% | 0.02% | -48.7% |
| Q2 2023 | $4,538,004 | -45.7% | 210,385 | -26.2% | 0.04% | -51.2% |
| Q1 2023 | $8,362,046 | +102.2% | 285,005 | +154.6% | 0.08% | +135.3% |
| Q4 2022 | $4,135,592 | -54.9% | 111,924 | -65.6% | 0.03% | -55.8% |
| Q3 2022 | $9,168,000 | – | 325,700 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 5,472,033 | $154,038,000 | 4.47% |
| Ghost Tree Capital, LLC | 550,000 | $15,483,000 | 4.35% |
| Ghost Tree Capital, LLC | 500,000 | $14,075,000 | 3.95% |
| Bain Capital Life Sciences Investors, LLC | 1,023,214 | $28,803,000 | 3.44% |
| Boxer Capital, LLC | 2,084,000 | $58,665,000 | 3.30% |
| Alpha Wave Global, LP | 700,635 | $19,723,000 | 2.33% |
| Soleus Capital Management, L.P. | 429,336 | $12,086,000 | 1.64% |
| Ikarian Capital, LLC | 250,000 | $7,037,000 | 1.40% |
| Cormorant Asset Management, LP | 610,000 | $17,172,000 | 1.20% |
| SECTORAL ASSET MANAGEMENT INC | 205,400 | $5,782,000 | 1.14% |